Supernus Pharmaceuticals, Inc. (SUPN)
SUPN Stock Price Chart
Key Info
| Market Cap | 1.15B |
| Revenue (ttm) | 477.29M |
| Net Income (ttm) | 129.31M |
| Shares Out | 52.66M |
| EPS (ttm) | 2.41 |
| PE Ratio | 9.03 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 3 |
| Last Price | $21.76 |
| Previous Close | $21.67 |
| Change ($) | 0.09 |
| Change (%) | 0.42% |
| Day's Open | 21.77 |
| Day's Range | 21.58 - 22.28 |
| Day's Volume | 365,095 |
| 52-Week Range | 14.45 - 25.05 |
SUPN Stock News
LOS ANGELES--(BUSINESS WIRE)---- $SUPN #classaction--The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) ...
BENSALEM, Pa.--(BUSINESS WIRE)---- $SUPN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
ROCKVILLE, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...
LOS ANGELES--(BUSINESS WIRE)---- $SUPN #CLASSACTION--Glancy Prongay & Murray LLP, Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc (SUPN) on Behalf o...
ROCKVILLE, Md., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...
NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus or the "Company") (NASDAQ: SUPN). Such investo...
ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2020 Results - Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2020 Results - Earnings Call Transcript
Supernus (SUPN) delivered earnings and revenue surprises of 174.07% and 18.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...
ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...
Investors who are looking for high return investments might be interested in the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt's method) a...
Greg Patrick to Retire as Chief Financial Officer Greg Patrick to Retire as Chief Financial Officer
Supernus is solidly on track for a new record of net sales this year and is still generating huge amounts of free cash flow.
These stocks are just temporarily inconvenienced large caps in the making.
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.
ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...
ROCKVILLE, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...
ROCKVILLE, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2020 Results - Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2020 Results - Earnings Call Transcript
Supernus (SUPN) delivered earnings and revenue surprises of 85.71% and 0.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, Md., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...
ROCKVILLE, Md., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...
Supernus (SUPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gold, silver, miners/GSMs outperformed nicely in Q2, and should continue to do extremely well going forward.
ROCKVILLE, Md., June 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...
As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.
Creates leading CNS portfolio with five marketed products, two product candidates in late-stage development, and robust pipeline Creates leading CNS portfolio with five marketed products, two ...
ROCKVILLE, Md., May 15, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment ...
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2020 Results - Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2020 Results - Earnings Call Transcript
Supernus (SUPN) delivered earnings and revenue surprises of 33.33% and 11.47%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, Md., April 28, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ROCKVILLE, Md. and CAMBRIDGE, Mass., April 21, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing prod...
ROCKVILLE, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...
Jazz Pharma's Mixed Earnings, And Other News: The Good, Bad And Ugly Of Biopharma
Shares slumped after the commercial-stage biopharma reported mixed results.
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q4 2019 Results - Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q4 2019 Results - Earnings Call Transcript
Supernus (SUPN) delivered earnings and revenue surprises of 8.77% and -6.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
SPN-812 (viloxazine hydrochloride), a once-daily novel serotonin norepinephrine modulating agent (SNMA), demonstrates a reduction in ADHD-RS-5 total score as early as Week 1 and continuing unt...
Is Supernus Pharmaceuticals (SUPN) a great pick from the value investor's perspective right now? Read on to know more.
ROCKVILLE, Md., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...
SPN-812 (viloxazine hydrochloride), a novel serotonin norepinephrine modulating agent (SNMA) SPN-812 (viloxazine hydrochloride), a novel serotonin norepinephrine modulating agent (SNMA)
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2019 Results - Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2019 Results - Earnings Call Transcript
Supernus (SUPN) delivered earnings and revenue surprises of -8.47% and -6.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
About SUPN
Supernus Pharmaceuticals, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. The company offers Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and in children 6 to 17 years of age; and Trokendi XR, an extended release topiramate, which is used for the prophylaxis of migraine headache, as well as for the treatment of epilepsy. Its prod... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date May 1, 2012 |
| CEO Jack Khattar | Employees 464 |
| Stock Exchange NASDAQ | Ticker Symbol SUPN |
Financial Performance
In 2019, SUPN's revenue was $392.76 million, a decrease of -3.95% compared to the previous year's $408.90 million. Earnings were $113.06 million, an increase of 1.86%.
Analyst Forecasts
According to 4 analysts, the average rating for SUPN stock is "Buy." The 12-month stock price forecast is 27.75, which is an increase of 27.53% from the latest price.